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Abstract
For more than 20 years, researchers have attempted to identify diagnostic and prognostic biomarkers for psychia-
tric disorders including schizophrenia, major (unipolar) depression, and bipolar disorder. Advocates of this research
contend that identifying such biomarkers will aid in the diagnosis of these disorders, as well as the possible devel-
opment of effective psychiatric medications to treat them. Currently, there are no diagnostic tests available. This is
largely due to the multi-factorial nature of psychiatric disorders. Biomarker testing of individuals is also prohibitively
expensive because significant expertise is required to conduct tests and follow-up counseling for the patient is
often necessary. It is cautioned that widespread biomarker testing could lead to negative consequences such as
discrimination in health insurance and employment, as well as selective abortion.
Correspondence
There are no clinical laboratory tests to date that can be
used by clinicians to diagnose patients with psychiatric
disorders. Instead, psychiatrists have to rely on the
patient’s description of symptoms, mental status exami-
nations, and clinical behavioral observations in order to
make an accurate diagnosis in line with the diagnostic
categories listed in the Diagnostic and Statistical Manual
of Mental Disorders 4th Edition (DSM-IV) [1] or the
International Statistical Classification of Diseases and
Related Health Problems 10
th Revision (ICD-10) [2].
Unfortunately, it can take months or even years for clin-
icians to make a correct psychiatric diagnosis using cur-
rent methods and there is much room for error.
Quantitative criteria are lacking for specific psychiatric
disorders, and many diagnostic criteria overlap.
It has been widely accepted that etiological diagnosis
of medical illness is superior to syndromal (symptom-
based) diagnosis. Scientific investigations into biomar-
kers for schizophrenia, major depression, and bipolar
disorder have the goal of generating more definitive
diagnostic tools for these disorders. The multidisciplin-
ary approach of Convergent Functional Genomics [3]
has revealed multiple candidates. This approach inte-
grates animal model gene expression data with human
genetic linkage/association data, as well as human tissue
(postmortem brain, blood) data, to cross-validating find-
ings, extract meaning from large datasets, and prioritize
candidate genes, pathways, and mechanisms for subse-
quent hypothesis-driven research [4]. These potential
biomarkers can be divided into three primary categories:
protein-based, imaging-linked, and genetic (see [5] for a
recent review).
Easily accessible bodily fluids like blood, urine, and
cerebral spinal fluid (CSF) are potential sources for the
identification of protein-based psychiatric biomarkers.
CSF, however, is probably the most relevant source for
identifying protein biomarkers for patients with psychia-
tric disorders because proteins that have been secreted
or shed from brain cells can be found there. These pro-
teins also can be found in the blood due to an exchange
with CSF; however, their levels are much reduced. As a
result, researchers are focusing on CSF as a means for
biomarker discover and blood for an eventual clinical
diagnostic assay.
Huang et al. utilized surface-enhanced laser desorption
ionization mass spectrometry in a total of 179 cere-
brospinal fluid samples (58 schizophrenia patients, 16
patients with depression, 5 patients with obsessive-com-
pulsive disorder, 10 patients with Alzheimer disease, and
90 controls). They discovered three key schizophrenia-
specific alterations in the up-regulation of a 40-amino
acid VGF-derived peptide, the down-regulation of trans-
thyretin at 4 kDa, and a peptide cluster at 6,800-7,300
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charged ions of the transthyretin protein cluster) [6].
Genetic biomarkers are specific genes, mutations, and
single nucleotide polymorphisms (SNPs) that can be
linked to psychiatric symptoms. In one study, using
blood samples from patients with mood disorders, the
investigators were able to determine 11 different bio-
marker candidates: 5 genes involved in myelination and
6 genes involved in growth factor signaling [7]. There
was also prior evidence of the differential expression of
these genes in the postmortem brains of individuals suf-
fering from mood disorders.
To be truly useful, a psychiatric biomarker must have
predictive power and allow for the identification of at-
risk individuals [8]. Proponents of determining clinically
useful, cost-effective biomarkers believe it will enhance
patient management, improve treatment and therapeutic
response, and lead to targeted therapy tailored to the
individual [9]. They also point to the possibility of
increased positive outcome through early intervention.
Genetic biomarkers are one area in psychiatric disor-
ders that is being researched, but neuroimaging is
another research tool being investigated to aid in the
diagnosis and etiology of psychiatric illnesses. The gen-
eral hypothesis is that the neruoanatomy of people
afflicted with a psychiatric disorder will differ than those
who do not have a psychiatric disorder. One neuroima-
ging study by Borgwardt et. al investigating schizophre-
nia in twins demonstrated that monozygotic twins
afflicted with schizophrenia had reduced brain gray mat-
ter volume versus healthy monozygotic twins [10]. One
interesting observation of this study is that they also
included monozygotic twins in which one twin was
diagnosed with schizophrenia while the other was not
(discordant). In the discordant twins the one with schi-
z o p h r e n i ah a dr e d u c e dg r a ym a t t e rv o l u m ej u s tl i k et h e
concordant twins; however, the regions of reduced gray
matter volume were different. This finding suggests that
genetic influence elicits a different etiology than envir-
onmental influences on the same outcome of
schizophrenia.
General anxiety disorder (GAD) is another psychiatric
disorder that affects many people. Just like with schizo-
phrenia, there is extensive research underway to deter-
mine the etiology of GAD. Neuroimaging is one tool
researches are using to decipher this disorder. Using
MRI, researchers found that people afflicted with GAD
had different amygdalar connectivity than control sub-
jects [11]. The amygdalae are part of the limbic system
and are responsible for developing memories tied to
emotional events. MRI is also being used to investigate
neuroanatomy differences in people diagnosed with
obsessive-compulsive disorder (OCD). One recent study
showed that people with OCD had different cortical
folding versus control subjects [12]. Neuroimaging to
detect differences in neuroanatomy in those with psy-
chiatric disorders is in its infancy, but will likely lead to
great advancements in the treatment, diagnosis, and
understanding of these disorders.
Another area of intense research is on inflammatory
agents that may add to the complexity of psychiatric
disorder development. Inflammatory agents such as
cytokines or specific hormones have been implicated as
markers of psychiatric disorders. This is mainly due to
the observation that people afflicted with depression
have higher inflammatory markers such as interleukin-6
or cortisol [13-15]. In one study researchers measured
the inflammatory response of pregnant women receiving
the flu vaccine [13]. As a marker of inflammation
researchers used macrophage migration inhibitory factor
(MIF), a cytokine up-regulated during inflammation.
The flu vaccine was used as an in vivo antigen challenge,
which all women who are pregnant during flu season
should get. The women were separated by depression
status. The authors observed that women previously
diagnosed with major depressive disorder or bipolar had
higher MIF responses than those women with no psy-
chiatric disorder, suggesting a dysregulation of inflam-
matory responses during depression.
Thorough assessment, however, is needed before we
are to completely change the way in which we diagnose
and treat patients with psychiatric disorders. Instead of
simply focusing on its potential, a closer look at the




The first major issue associated with any new technol-
ogy is almost always its cost; biomarker screening is no
exception. Diagnostic testing can be extremely expen-
sive. Genetic testing can cost anywhere from $100 to
$3,000 per patient [16]. For example, implementing a
screening program for people with a family history of
s c h i z o p h r e n i aw o u l db eah u g ec o s tb u r d e no ni n s u r -
ance companies, health maintenance organizations, or
the patients themselves. If an individual tests positive
for a genetic biomarker, additional funds may be needed
for post-screening support and counseling and/or treat-
ments for the disorder.
Currently, implementing such screening programs is
not worth the investment since genetic biomarkers are
not yet highly predictive of psychiatric disease. In the
case of one likely genetic biomarker for schizophrenia
(neuregulin 1), the most promising findings to date
account for only a 1% increased risk of developing
symptoms [8]. Thus, despite the high heritability of schi-
zophrenia, single genes only make a very small
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to be cost effective, any future clinical diagnostic criteria
that includes biomarker screening should also take into
consideration a patient’s reported symptoms, especially
those that interfere with their daily life [1]. This way,
only individuals who are considerably afflicted by mental
disorders will be treated.
Unreliability
O n eo ft h er e a s o n sf i n d i n gg e n e t i cb i o m a r k e r si ss o
challenging is that most mental disorders are considered
multi-factorial; multiple genes or gene families trigger
disease manifestation. Commonly referred to as poly-
genic inheritance, it is believed that specific “gene sets”
or “gene combinations” contribute to the development
of symptoms. Although investigations are ongoing, we
do not know the identity of many of the genes that play
a significant role in the genesis of mental illness or the
major pathways in which they participate. The linkage
of a few genes or gene products to the wide-variety of
psychiatric symptoms cannot reliably be used for the
diagnosis of mental disorders [17].
The influence of the environment on psychiatric dis-
orders also needs to be considered. Schizophrenia stu-
dies involving monozygotic twins have shown that twins
may have the same genotype, but not have the same
phenotype [18], with one twin going on to develop schi-
zophrenia while the other does not. Non-genetic factors
may play a key role in disease development and progres-
sion. Socio-economic statuses, access to technology, and
even religious influence have been shown to modify the
onset and severity of psychiatric disorders. For example,
a lower socio-economic status is associated with an
increased risk of mental illness and psychiatric hospitali-
zation [19,20]. Religious belief has been shown to aid
recovery in patients with schizophrenia. In one study,
increased religious activity was associated with a
decrease in symptoms [21]. However, religion can also
become part of the patient’s problem if they are rejected
by their faith community, burdened by spiritual activ-
ities, and demoralized by their beliefs [22]. Since those
afflicted by psychiatric disorders will not be exposed to
the same environmental influences, it is unwise to make
generalizations based solely on genetic biomarkers.
The introduction of diagnostic biomarkers can only
provide limited information on the likelihood of psychia-
tric disorder development and only on a patient-by-
patient basis. Environmental influences and lifestyle
choices figure heavily in disease progression and gene
products do not function alone but in complex path-
ways; one gene may influence the behavior of other
genes when exposed to additional risk factors [23,24].
Additionally, biomarkers may be a variable as a function
of age, gender, ethnicity, and health status of the patient.
Researchers have already found that the onset of
schizophrenia is influenced by gender. A study con-
ducted by Häfner indicated that schizophrenia tends to
affect women 3 to 4 years later than men and women
tend to have milder forms of the disease in their
younger years. The author attributed this delayed onset
to the protective effects of estrogen [25].
Although extensive research is under way, genetic
detection, neuroimaging, or inflammatory responses as
means of detecting, treating, or diagnosing psychiatric
disorders is still in its infancy. While research efforts to
find better and more accurate ways for detection are
good natured, the implications of these new means of
detection is not always well thought out. If a person
expresses a certain gene or gene set indicative of a men-
tal health condition, but has no symptoms do they have
the condition or not? There is always the question: did
an environmental influence cause a change in gene
expression that led to a specific disorder? Most psychia-
tric disorders are not diagnosed in childhood, yet a per-
son is born with their genetic makeup. There is some
missing factor not answerable with genetics alone that
leads to a specific phenotype. The same argument can
be made for neuroimaging or inflammatory responses.
Not every person that is diagnosed with a psychiatric
disorder will have a different neuroanatomic make up.
Not every person with a neuroanatomic difference will
have a psychiatric disorder. So, what will be the excep-
tion and what will be the rule?
Ethical Concerns
Perhaps the biggest concern related to prognostic bio-
markers, though, is whether testing would actually be of
any benefit to asymptomatic individuals. If researchers
could develop a blood test for schizophrenia in the next
few years, what are the ethical implications for institut-
ing routine testing for “at-risk” individuals when there is
currently a lack of preventative therapeutic strategies
[26]?
Potential for Biomarker Misuse
Research into the identification of biomarkers for psy-
chiatric disorders has raised ethical questions, especially
concerning the collection and usage of genetic informa-
tion. Hereditary information is uniquely personal. It can
foretell an individual’s medical future, divulge personal
information about one’s parents, siblings and children,
and has a history of being used to stigmatize and victi-
mize individuals [27].
Discrimination
Since the eruption of the HIV/AIDS pandemic there
have been numerous debates as to whether people diag-
nosed with HIV/AIDS should be classified as a pro-
tected demographic under non-discriminatory legislation
[28]. The discovery of HIV/AIDS was made over two
decades ago and despite extensive research and
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afflicted with the disease. Questions that still arise, ask
whether these people should have a right to privacy
concerning matters associated with their illness [29,30].
Discrimination is still a problem for this demographic;
one study published this year showed that HIV/AIDS
sufferers have a harder time finding dental care. Some
were refused once they disclosed their illness and the
discrimination was more pronounced if the patient was
African-American [31].
Another stigmatizing disease is tuberculosis (TB),
which was once eradicated from the US but is on the
rise again. Recent studies have shown that people’s lack
of knowledge about TB has driven an overt discrimina-
tion against TB sufferers [32,33]. The media has contrib-
uted to this stigma by sensationalizing rare cases of
antibiotic-resistant TB strains. One study published in
2008 reported that people given a survey asking about
their knowledge of TB knew that it was an infectious
disease that affected the lungs, but when asked how it
was transmitted some thought TB was acquired via sex-
ual transmission [32].
Based on recent studies, there is still a stigma attached
to diseases such as HIV/AIDS and TB that have exten-
sive research and knowledge about causative agents,
transmission, and treatment. Yet people, including the
healthcare field, continue to discriminate against these
individuals. If there were a definitive test or biomarker
for psychiatric illness, psychiatric disorder patients
would likely be exposed to similar discrimination based
on historical findings of other stigmatizing disorders.
Unfortunately in research, science almost always pre-
cedes legislation.
One of the biggest concerns with the collection of
genetic or other biological information is that it can be
used as an employment and insurance screening tool to
deny an otherwise healthy individual employment or
healthcare coverage [34]. An actual case of such discri-
mination involved a mother who had an alpha1-anti-
trypsin deficiency, an autosomal recessive disorder that
can lead to emphysema and liver disease. In 2003, Heidi
Williams was denied health insurance for her two chil-
dren because they were carriers of the disease. This was
despite the fact they were both healthy and neither had
the two copies of the allele necessary to make them sick
[35]. A person is considered to have the disease (AAT
deficiency) only if both genes are inherited. Otherwise,
people with only one gene are considered ‘carriers’–in
this case, AAT levels are lower than normal, but do not
cause serious health problems.
In order to combat such prejudice, President Bush
signed the Genetic Information Non-discrimination Act
(GINA) in 2008, which prevents insurance companies
from denying coverage or increasing premium rates to
otherwise healthy individuals on the basis of genetic
information [36]. Employers are also barred from using
genetic information for hiring, firing, or job-placement
decisions [37].
However, the scope of this law is limited to “genetic
information,” which is defined as:
￿ An individual’s genetic test (including genetic tests
done as part of a research study);
￿ Genetic tests of the individual’sf a m i l ym e m b e r s
(defined as dependents and up to and including fourth
degree relatives);
￿ Genetic tests of any fetus of an individual or family
member who is pregnant, and genetic tests of any
embryo legally held by an individual or family member
utilizing assisted reproductive technology;
￿ The manifestation of a disease or disorder in family
members (family history);
￿ Any request for, or receipt of, genetic services or
participation in clinical research that includes genetic
services (genetic testing, counseling, or education) by an
individual or family member.
GINA does not protect the results of tests that do not
measure DNA, RNA, or chromosomal changes. There-
fore, there is nothing in the law to protect asymptomatic
individuals who test positive for non-genetic biomarkers
of psychiatric disease, leaving them vulnerable to
discrimination.
Selective Abortion
In the future, parents could conceivably employ prog-
nostic biomarker testing for major psychiatric disorders
after undergoing chorionic villus sampling. After receiv-
ing the results, these parents may decide to terminate
the pregnancy if the child is at risk for a psychiatric
abnormality. Couples undergoing in vitro fertilization
already have the opportunity to select against undesir-
able genetic conditions by means of a pre-implantation
genetic diagnosis. It is only a matter of time before psy-
chiatric biomarkers are added to the list of conditions
routinely screened for prenatally.
Ill-treatment
There is also the potential for misusing biomarkers in a
new wave of eugenics or sterilization campaigns. There
is a long history of the misuse of genetic information by
many governments to discriminate against those per-
ceived as genetically unfit and to restrict their reproduc-
tive decisions. In the United States, a program of
compulsory sterilization of mentally ill individuals began
in 1897 with the passage of legislation in Michigan.
However, the movement did not gain momentum until
1927 when the Supreme Court legitimized the forceful
sterilization of patients at a Virginia home for the men-
tally retarded in Beck v. Bell [38]. Over the next 15
years, the number of sterilizations steadily increased
until the case of Skinner v. Oklahoma complicated the
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ilization could not be imposed as a punishment for a
crime. Criminal sterilization laws were designed to tar-
get “criminality,” believed by some at the time to be a
hereditary trait. Such programs were eventually aban-
doned after World War II because of the association
between the eugenics movement and the Nazis. During
this period though, more than 65,000 individuals were
sterilized in 33 states [40].
Such practices are not simply relegated to the pages of
history. Current laws in China authorize the sterilization
of individuals who are genetic carriers of serious medical
disorders, including mental illnesses [41]. The Maternal
and Infant Healthcare Law of 1995 requires couples to
undergo a pre-marital medical examination. If the
r e s u l t so ft h i se x a m i n a t i o nr e v e a la“genetic disease of a
serious nature which is considered to be inappropriate
for child-bearing,” the couple must take “long-term con-
traceptive measures” or undergo a sterilization proce-
dure before they can get married [42].
Conclusion
The eventual use of biomarkers for psychiatric diagnosis
will need to be implemented with caution and with full
awareness of the costs involved. Compared to current
measures of disease diagnosis, such as behavioral obser-
vation or questionnaires, the use of biomarkers is a
more labor-intensive approach and requires a higher
level of expertise.
The long-term impact that results may have on future
life choices for the individual and family members must
also be investigated as genetic testing could potentially
introduce misleading labels and limit an individual’s
opportunities. One needs to closely weigh the costs
against the benefits because currently there are no reli-
able biomarkers that can consistently predict mental
illness.
In the rush toward developing etiological screening
tools, it must be remembered that the patient is at the
heart of the medical profession, not their DNA. Any
new diagnostic tools should confer a significant benefit
to patients and not promote confusion, discrimination,
or stigma.
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